Brain serotonin 5-HT1A receptor binding in human mesial temporal lobe epilepsy measured by positron emission tomography and [11C]WAY-100635 - WAY and epilepsy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004156-39-AT

Enrollment

Unknown

Registered

2005-10-14

Start date

2005-11-18

Completion date

Unknown

Last updated

2016-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Application of [11C]WAY-100635, a brain serotonin 5-HT1A receptor ligand, in patients with mesial temporal lobe epilepsy

Interventions

Pharmaceutical Form: INN or Proposed INN: [11C]way 100635 Concentration unit: MBq/ml megabecquerel(s)/millilitre

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: recruitment of patients from the Epilepsy monitoring Unit of the Dep. of Neurology. confirmation of diagnosis by video EEG monitoring including invasive EEG. typical MRI alterations Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: The main objectives are: 1) is WAY 100635 a marker of the epileptogenic region? ;Secondary Objective: 2) is there an involvement of extratemporal regions and of the serotonergic system? 3) is there an correlation between binding alteration and psychopathological findings?;Primary end point(s): comparison of 20 patients with an alreadyexisting norm population	—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026